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Abstract
Background: Intermittent preventive treatment (IPT) is a promising malaria control strategy; however, the optimal regimen
remains unclear. We conducted a randomized, single-blinded, placebo-controlled trial to evaluate the efficacy, safety, and
tolerability of a single course of sulfadoxine-pyrimethamine (SP), amodiaquine + SP (AQ+SP) or dihydroartemisinin-
piperaquine (DP) among schoolchildren to inform IPT.
Methods: Asymptomatic girls aged 8 to 12 years and boys aged 8 to 14 years enrolled in two primary schools in Tororo,
Uganda were randomized to receive one of the study regimens or placebo, regardless of presence of parasitemia at
enrollment, and followed for 42 days. The primary outcome was risk of parasitemia at 42 days. Survival analysis was used to
assess differences between regimens.
Results: Of 780 enrolled participants, 769 (98.6%) completed follow-up and were assigned a treatment outcome. The risk of
parasitemia at 42 days varied significantly between DP (11.7% [95% confidence interval (CI): 7.9, 17.1]), AQ+SP (44.3% [37.6,
51.5]), and SP (79.7% [95% CI: 73.6, 85.2], p,0.001). The risk of parasitemia in SP-treated children was no different than in
those receiving placebo (84.6% [95% CI: 79.1, 89.3], p=0.22). No serious adverse events occurred, but AQ+SP was associated
with increased risk of vomiting compared to placebo (13.0% [95% CI: 9.1, 18.5] vs. 4.7% [95% CI: 2.5, 8.8], respectively,
p=0.003).
Conclusions: DP was the most efficacious and well-tolerated regimen tested, although AQ+SP appears to be a suitable
alternative for IPT in schoolchildren. Use of SP for IPT may not be appropriate in areas with high-level SP resistance in Africa.
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Introduction
Despite renewed global commitment to malaria control and
substantial increases in funding, the burden of malaria in Africa
remains high [1]. Typically, malaria control efforts focus on young
children and pregnant women, who bear the greatest burden of
morbidity and mortality. Older children are generally protected
from the most serious effects of illness by antimalarial immunity
acquired through repeated infections [2]. However, malaria in
school-aged children remains common and can substantially
reduce school attendance, cognition, and learning [3]. Older
children also serve as a major reservoir of parasites, contributing to
transmission in the wider community. Yet surprising little is known
about how best to control malaria in schools [4,5].
Available and proven malaria control interventions include
insecticide-treated bed nets (ITNs), indoor residual spraying (IRS)
of insecticide, and effective case management. However, even with
ITNs and effective management with artemisinin-based combina-
tion therapies (ACTs), children living in highly endemic areas are
frequently infected [6]. Intermittent preventive treatment (IPT),
the administration of curative doses of antimalarial treatment at
predefined intervals regardless of infection status, is gaining
momentum as a malaria control strategy [7]. IPT has been shown
to benefit infants [8], children in areas of seasonal malaria
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the World Health Organization recently released a new policy on
IPT in infants [15]. However, a number of scientific and
operational issues for IPT remain to be determined, and the
optimal regimen remains unclear [16]. Sulfadoxine-pyrimeth-
amine (SP) has been most widely studied for IPT and is currently
recommended in pregnancy, but there is evidence that IPT with
SP in pregnancy is ineffective in areas of high SP resistance
[17,18]. The efficacy and safety of alternatives for IPT is little
studied.
We conducted a randomized, single-blinded, placebo-con-
trolled trial, modeled on standard antimalarial drug efficacy
trials, to evaluate three regimens available for IPT in Ugandan
schoolchildren: SP, amodiaquine combined with SP (AQ+SP),
and dihydroartemisinin-piper a q u i n e( D P ) .T h ep r i m a r yo u t -
come was the 42-day risk of parasitemia. Our aim was to
compare the efficacy of the regimens for eliminating asymp-
tomatic infections and preventing new infections, and to assess
the safety, tolerability, and acceptability of the regimens, after a
single course of treatment. The inclusion of the placebo arm
allowed us to evaluate the efficacy of SP among asymptomatic
children with acquired immunity in an area with substantial
resistance, and to assess the risk of adverse events with each of
the regimens.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics
The study was approved by the Ugandan National Council for
Science and Technology, the ethics committees of Makerere
University and the London School of Hygiene and Tropical
Medicine, and the Ugandan National Drug Authority. The trial
was overseen by an independent Data and Safety Monitoring
Board. Permissions were obtained from district officials and
teachers.
Study site
The trial was conducted between February and July 2008 in two
primary schools in Tororo district, Uganda, where the estimated
entomological inoculation rate in 2001-02 was 562 [19], and up to
60% of children were parasitemic in 2008 [20]. In prior studies of
symptomatic patients, the risk of recrudescence at 28 days was
35% with SP in Kampala [21], and 18% with AQ+SP [22] and
0.3% with DP in Tororo [23]. The prevalence of parasite genetic
polymorphisms associated with decreased sensitivity to both SP
and AQ is high in Uganda. The five mutations that mediate an
intermediate level of resistance to SP (dhfr N51I, C59R, and
S108N and dhps A437G and K540E) are very common in Tororo
(over 80% prevalence) [24]; however, the dhfr I164L and dhps
A581G mutations, which mediate higher-level resistance, are
uncommon [25]. For AQ, the pfcrt 76T mutation is fixed at nearly
100% prevalence, and the pfmdr1 N86Y and D1246Y mutations
are also over 80% in Tororo [26].
In 2004, the Ugandan Ministry of Health selected the
combination of artemether-lumefantrine to replace chloroquine
+ SP as first-line treatment for uncomplicated malaria. Although
the new antimalarial policy was adopted in 2004, it was not fully
implemented until 2006, and non-recommended regimens con-
tinue to be used frequently in Uganda due to stock-outs of
artemether-lumefantrine [27].
Participants
School meetings were held to explain the study and written
informed consent was sought from parents/guardians of girls aged
8 to 12 years, and boys aged 8 to 14 years, enrolled in classes 1 to
7. Assent to participate was sought from all children. Additional
selection criteria included: no known allergy or prior adverse
reaction to study medications; no onset of menstruation; no fever
(axillary temperature ,37.5uC) or history of fever in previous
24 hours; no evidence of severe malaria or danger signs; no
ongoing antimalarial treatment; hemoglobin .7.0 g/dL; and
parasite density #10,000/ml.
Enrollment procedures
At enrollment (day 0), we conducted a standardized assessment
of symptoms, which served as the baseline for monitoring of
subsequent adverse events. A physical examination was conducted,
including measurement of temperature, height and weight. A
fingerprick blood sample was obtained for hemoglobin measure-
ment, thick and thin blood smears, and to store on filter paper.
Interventions
On day 0, children were randomly assigned to receive SP
(Fansidar, Roche, 500 mg/25 mg tablets, 25 mg/kg sulfadoxine and
1.25 mg/kg pyrimethamine per treatment as a single dose), AQ+SP
(Camoquin, Parke-Davis, 200 mg tablets, 10 mg/kg on days 0 and 1,
and 5 mg/kg on day 2), DP (Duocotexin, Holley Pharm, 40 mg
dihydroartemisinin/320 mg piperaquine tablets targeting a total dose
of 6.4 and 51.2 mg/kg of dihydroartemisinin and piperaquine,
respectively, given in 3 equally divided daily doses to the nearest J
tablet), or placebo (Cosmos Limited, Nairobi, Kenya) administered to
simulate the amodiaquine dosing schedule. Children in the SP group
also received placebo tablets on days 1 and 2.
Randomization and treatment administration
Randomization codes were computer-generated in blocks of
eight by an investigator not directly involved in the project and
were sealed in numbered envelopes. The study nurse assigned
treatment numbers sequentially and allocated treatments by
opening the envelope corresponding to the treatment number.
All other study personnel were blinded to treatment assignments.
Children were not informed of their treatment regimen, but the
color and taste of study medications were dissimilar. All treatment
was directly observed. After drug administration, children were
observed for 30 minutes and treatment was re-administered if
vomiting occurred. No child vomited more than once.
Follow-up visits
Children were followed-up at school on days 1, 2, 3, 7, 14, 28
and 42, and any additional day that they felt ill. Children absent
for scheduled follow-up were visited at home. Follow-up
evaluations consisted of a standardized history and physical
examination. Fingerprick blood samples were taken on days 7,
14, 28, 42, (and on any unscheduled day that fever was reported)
to repeat thick blood smears and for storage on filter paper.
Hemoglobin was reassessed on day 42. Children with a
hemoglobin ,10 g/dL were treated with ferrous sulfate for 14
days according to the Integrated Management of Childhood
Illnesses guidelines. Acceptability of the study regimens was
assessed using a semi-structured questionnaire administered on
day 7. Children were excluded if consent to participate was
withdrawn or if they were lost to follow-up. Children who received
antimalarial drugs outside of the study were followed for 42 days
but were not assigned an efficacy outcome.
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danger signs or severe malaria with parasitemia; parasite density
.10,000/ml; fever (axillary temperature .37.5uC) or history of
fever in the previous 24 hours on days 3 to 42 with parasitemia;
presence of parasitemia on day 42. All children who received
rescue therapy were followed for the full 42 days. Children found
to have illnesses other than malaria received standard of care, or
were referred appropriately.
Laboratory evaluations
Blood smears were stained with 2% Giemsa for 30 minutes.
Parasite densities were determined from thick blood smears by
counting the number of asexual parasites per 200 white blood
cells (or per 500 if the count was less than 10 parasites/200 white
cells), assuming a white blood cell count of 8,000/ml. A smear was
considered negative after reviewing 100 high-powered fields.
Gametocytemia was also determined using similar methodology.
Figure 1. Trial profile. SP = sulfadoxine-pyrimethamine; AQ+SP = amodiaquine + sulfadoxine-pyrimethamine; DP = dihydroartemisinin-
piperaquine; PD = parasite density.
doi:10.1371/journal.pone.0013438.g001
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independent microscopists read the slides, with a third micros-
copist resolving discrepant results. Because microscopy results
were generally not available until the following day, a child could
be excluded after randomization and treatment if the parasite
density was .10,000/ml. Hemoglobin concentration was mea-
sured using a portable spectrophotometer (HemoCue, A ¨ngel-
holm, Sweden).
Molecular genotyping techniques were used to distinguish
recrudescent from new infections in children who were para-
sitemic at baseline and developed recurrent parasitemia between
days 3 and 42. DNA was isolated from filter paper blood samples
collected at enrollment and on the day of recurrent parasitemia
using chelex extraction. Paired samples were genotyped in a
stepwise fashion using msp-2, msp-1, and four microsatellites [28].
If, for any of the six loci, an allele was not shared between day 0
and day of recurrence, the infection was classified as a new
infection. If at least one allele was shared between day 0 and day of
recurrence at all six loci, the infection was classified as a
recrudescence.
Sample size and outcomes
Sample size was calculated to test the hypothesis that treatment
with AQ+SP or DP would decrease the 42-day risk of parasitemia
(the primary outcome) compared to treatment with SP, assuming a
risk of 65% in SP-treated children. We calculated that 190
children per arm would be needed to detect a significant difference
of $15% (p,0.05, two-sided test), with 80% power, allowing for
10% loss to follow-up [29]. No formal adjustments for multiple
comparisons were made. Secondary outcomes included risks of
recrudescence and new infection (adjusted by genotyping), and
change in mean hemoglobin from Day 0 to Day 42. Safety
outcomes included risks of common and serious adverse events.
Statistical methods
Data were entered and verified using Epi-Info version 6.04 and
analyzed using STATA version 10.0 (STATA Corporation,
College Station, TX, USA). The 42-day risk of parasitemia was
estimated using Kaplan-Meier survival techniques with corre-
sponding 95% confidence intervals (CI) calculated using Green-
wood variance estimates [30]. Children who were excluded or
received antimalarials outside the study were censored on the day
that these events were identified. Risk differences were estimated
and formal hypothesis testing done using unpaired z-tests. A Cox’s
Proportional Hazards model was fitted to adjust for baseline
imbalances in the presence of parasitemia. Since we expected the
rate of parasitemia to differ between regimens over the study
period due to varying drug half-lives, the model was fitted with an
interaction between treatment regimen and time band (0–14 days,
15–28 days, 29–42 days), assuming proportional hazards within
each time band [30].
The proportions of children receiving rescue therapy were
compared using the chi-squared test. The risks of recrudescence
and new infections were also estimated using Kaplan-Meier
techniques, as described above. When estimating the risk of
recrudescence only children who were parasitemic at baseline
were included in the analysis and those children experiencing a
new infection were censored on the day of the infection. When
estimating the risk of new infection only children who were not
parasitemic at baseline were included in the analysis. Two-sided t-
tests were used to compare the mean change in hemoglobin
between days 0 and 42.
An adverse event was defined as any untoward medical
occurrence, irrespective of its suspected relationship to the study
medications. All events were graded by severity and relationship to
study treatment [31]. The risk of experiencing an adverse event
was estimated using Kaplan-Meier techniques, censoring for those
who received rescue therapy. Comparisons with placebo were
made using z-tests. Quantitative data on acceptability of different
treatment regimens were compared to those of placebo using chi-
square and Fisher’s exact tests.
Results
Participant flow
Of 894 children initially screened, 794 (88.8%) met the
inclusion criteria and were randomized to one of the treatment
Table 1. Baseline characteristics by treatment regimen.
Characteristic Treatment regimen (N=780)
Placebo SP AQ+SP DP
Number of children 196 186 200 198
Gender (n female, %) 78 (39.8) 70 (37.6) 78 (39.0) 87 (43.9)
Mean age (SD, years) 10.6 (1.86) 10.6 (1.85) 10.7 (1.93) 10.3 (1.73)
Mean hemoglobin (SD, g/dL) 12.7 (1.38) 12.7 (1.31) 12.7 (1.33) 12.4 (1.26)
Bednet use* { (%) 57 (29.1) 47 (25.3) 56 (28.0) 56 (28.2)
Parasitemia { (%) 110 (56.4) 98 (52.7) 87 (43.5) 104 (52.8)
_P. falciparum 110 95 87 103
_P. falciparum/P. malariae 01 0 0
_P. malariae 01 0 1
_Not known 0 1 0 0
Gametocyte presence { (%) 22 (11.3) 14 (7.5) 17 (8.5) 11 (5.6)
Geometric mean parasite density per ml { (95% CI) 338.8 (255.9, 448.4) 409.6 (291.8, 574.3) 477.1 (333.1, 683.4) 325.5 (234.4, 451.0)
*Children who slept under a bednet last night.
{Two children were missing bednet data; 1 in SP and 1 in DP.
{Two children were missing blood smear data; 1 in placebo and 1 in DP.
doi:10.1371/journal.pone.0013438.t001
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.10,000/ml and were excluded after randomization. Of the 780
children enrolled, 769 (98.6%) completed follow-up and were
included in the primary outcome analysis. The characteristics of
participants randomized to each treatment were similar, although
children receiving AQ+SP were less likely to be parasitemic
(Table 1). Just over half (399 [51.3%]) of children were parasitemic
at enrollment. Nearly all infections were P. falciparum.
42-day risk of parasitemia
At day 42, there was no evidence that SP provided any benefit
over placebo (Table 2) even after adjusting for the presence of
baseline parasitemia (data not shown). The risk of parasitemia in
children treated with DP and AQ+SP was significantly lower than
in those receiving SP, and DP was superior to AQ+SP (risk
difference 32.6 [95% CI 24.3, 40.9]; p,0.001).
Risk of rescue therapy
Of 421 children who were parasitemic during follow-up, only
30 (7.1%) developed symptomatic malaria, requiring rescue
therapy with artemether-lumefantrine (13 in the placebo group,
13 SP, 3 AQ+SP, and 1 DP). Only one child, who received
placebo, developed symptoms within 7 days of treatment (on day
3). An additional 24 (5.7%) children received rescue therapy for
a parasite density .10,000/ml in the absence of fever (14
p l a c e b o ,7S P ,2A Q +S P ,a n d1D P ) .T h eo v e r a l lr i s ko fr e s c u e
therapy was significantly lower in children receiving AQ+SP
(2.5%, p=0.001) or DP (1.0%, p,0.001), than in those treated
with SP (10.7%).
Risk of recrudescence
Of 399 children who were parasitemic at baseline, 228 were
parasitemic during follow-up. The child who received rescue
therapy on day 3 was classified as a recrudescence. Genotyping
results were available for 221 children; genotyping was
unsuccessful in 6 cases, and results were missing for one. Thus,
392 children were included in the analysis for risk of
recrudescence. There were 122 recrudescences, 99 new infec-
tions, and 171 who remained free of parasites. Children treated
with AQ+SP and DP were at significantly lower risk of
recrudescence than those receiving SP (Figure 2, Table 3).
There was no evidence that treatment with SP provided any
benefit over placebo.
Risk of new infection
Of 379 children who were free of parasites at baseline, 193
became parasitemic during follow-up and were classified as new
infections. Again, there was no evidence that SP provided any
benefit over placebo for prevention of new infections (Figure 3,
Table 3). Both AQ+SP and DP were more efficacious than
SP, but DP was superior for preventing new infections
(DP vs. AQ+SP: risk difference 36.0 [95% CI: 24.5, 47.6]
p,0.001).
Impact on hemoglobin
Mean hemoglobin fell between day 0 and day 42 in children
treated with SP (20.18 g/dL [95% CI: 20.38, 0.02]); the mean
change in SP-treated children was no different than in those
receiving placebo (20.24 g/dL [95% CI: 20.44, 20.05],
p=0.65). In contrast, day 42 hemoglobin in children receiving
AQ+SP and DP was substantially higher than at baseline
(increasing by 0.37 g/dL [95% CI: 0.18, 0.56] and 0.34 g/dL
Table 2. Risk of parasitemia at 42 days associated with the
treatment regimens as compared to SP.
Treatment n/N % Risk Risk difference p-value
(95% CI) (95% CI)
SP 147/186 79.7 (73.6, 85.2) — —
Placebo* 164/196 84.6 (79.1, 89.3) 24.9 (212.6, 2.9) 0.22
AQ+SP 87/200 44.3 (37.6, 51.5) 35.4 (26.3, 44.5) ,0.001
DP 23/198 11.7 (7.9, 17.1) 68.0 (60.6, 75.4) ,0.001
*One child in the placebo arm was lost to follow up on day 0 and hence was
censored on this day.
doi:10.1371/journal.pone.0013438.t002
Figure 2. Cumulative risk of recrudescence in children with malaria parasitemia at baseline over 42 days by treatment regimen.
SP = sulfadoxine-pyrimethamine; AQ+SP = amodiaquine + sulfadoxine-pyrimethamine; DP = dihydroartemisinin-piperaquine.
doi:10.1371/journal.pone.0013438.g002
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significantly greater than in SP-treated children (p,0.001 for both
comparisons). There was no evidence that mean change in
hemoglobin was different in children treated with AQ+SP and DP
(difference 0.03 [95% CI 20.24, 0.30] p=0.82).
Adverse events
By day 42, 973 adverse events were reported by 477 (61%)
children, including 897 (92%) mild events, 76 (8%) moderate and
no serious adverse events (Table 4). Overall, the risk of
experiencing any adverse event did not differ between the
regimens at day 42. However, within the first 3 days of treatment,
this risk was higher in children receiving AQ+SP than in those
receiving placebo (44.4% [95% CI: 37.8, 51.6] vs. 30.3% [95%
CI: 24.4, 37.2], respectively, p=0.003). The most common
adverse events reported were headache, cough, abdominal pain,
coryza, skin rash, nausea, vomiting, and diarrhea. Children
treated with AQ+SP were at significantly higher risk of vomiting
than those receiving placebo, which was greatest within the first 3
days after treatment. There was also a non-significant trend
toward increased risk of nausea associated with AQ+SP, which
was greatest soon after treatment (data not shown). Children
treated with AQ+SP or DP were significantly less likely to report a
history of fever or to be febrile than those receiving placebo.
Children were more likely to rate the taste of the tablets as
‘poor’ or ‘fair’ (than ‘good’ or ‘excellent’) if they were treated with
AQ+SP (67/199 [33.7%]) or DP (55/198 [27.8%]) than those
receiving placebo (20/195 [10.3%], p,0.001). However, most
children reported that they would be willing (657/775 [84.8%]) or
very willing (62/775 [8.0%]) to take the tablets each school term,
regardless of treatment group (94% placebo, 96% SP, 90%
AQ+SP, 91% DP).
Discussion
Intermittent preventive treatment of schoolchildren is a
promising malaria control strategy; however, with increasing SP
resistance the optimal drug regimen remains unclear. To offer
insights into the relative benefits of IPT with different antimalarial
regimens, we evaluated the impact of a single treatment in
Ugandan schoolchildren. We found a rank order in the efficacy of
study regimens, DP . AQ+SP . SP, with SP providing no benefit
over placebo. DP and AQ+SP were also associated with a marked
improvement in hemoglobin levels. All regimens were safe and
acceptable, although children treated with AQ+SP were at higher
risk of vomiting, particularly early after treatment, suggesting that
this regimen was less well-tolerated. Our findings suggest that DP
will be highly efficacious for IPT in schoolchildren, and that
AQ+SP may be a suitable alternative, but that SP should not be
used for IPT in areas with high-level SP resistance, as occurs in our
study site.
Of the regimens available for IPT, SP has several advantages
that make it attractive including low cost, documented safety,
simple dosing and a relatively long elimination half-life. However,
resistance to SP has become widespread in Africa, which could
limit the utility of this regimen [32]. Benefits of IPT with SP have
Table 3. Risk of recrudescence in children with parasites on
Day 0 (adjusted by genotyping) and risk of new infection in
children who were free of parasites on Day 0.
Treatment n/N % Risk (95% CI)
Risk difference
(95% CI) p-value
Risk of recrudescence in children with parasites on day 0 (n=392)
SP 50/98 65.0 (52.8, 76.9) — —
Placebo 64/109 71.0 (60.1, 81.2) 26.1 (222.4, 10.3) 0.47
AQ+SP 6/82 8.1 (3.7, 17.2) 56.8 (43.0, 70.7) ,0.001
DP 2/103 2.0 (0.5, 7.7) 63.0 (50.4, 75.6) ,0.001
Risk of new infection in children who were free of parasites on day 0
SP 62/88 70.4 (60.8, 79.6) — —
Placebo 64/85 75.3 (65.8, 83.9) 24.8 (218.1, 8.4) 0.47
AQ+SP 55/113 49.1 (40.3, 58.7) 21.4 (8.1, 34.7) 0.002
DP 12/93 13.1 (7.7, 21.9) 57.4 (45.6, 69.1) ,0.001
doi:10.1371/journal.pone.0013438.t003
Figure 3. Cumulative risk of new infection in children free of malaria parasites at baseline over 42 days by treatment regimen. SP =
sulfadoxine-pyrimethamine; AQ+SP = amodiaquine + sulfadoxine-pyrimethamine; DP = dihydroartemisinin-piperaquine.
doi:10.1371/journal.pone.0013438.g003
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children [11]. However, recent studies conducted in areas with
high-level SP resistance suggest that the drug offered no benefit
when administered for IPT in pregnant women [17,18], and
infants [34]. The threshold level of resistance beyond which IPT
with SP ceases to be effective is unknown, but even when
resistance is prevalent, SP may still have a role [33]. Host
immunity, which in endemic areas increases with age, is likely to
modify the relationship between resistant parasites and treatment
outcome [24]. SP may remain effective for prevention of malaria
in older children and adults with relatively high levels of acquired
antimalarial immunity. However, in our study area, where
resistance is common, SP provided no benefit to older children.
DP, a newer ACT regimen, was the most efficacious and best-
tolerated regimen in this study. In Senegal, piperaquine combined
with dihydroartemisinin (DP) and with SP (SP+P) administered to
children under five for IPT during the high transmission season
were as effective as AQ+SP for preventing malaria, and were
better tolerated [12]. In Mali, two other ACTs, artesunate + SP
(AS+SP) or amodiaquine + artesunate (AQ+AS), administered to
schoolchildren during the malaria transmission season reduced
clinical malaria incidence, asymptomatic parasitemia, and anemia
[14]. However, use of an ACT regimen for IPT may not be
desirable if an ACT is used as first-line treatment of uncomplicated
malaria, as is currently the case in most of sub-Saharan Africa,
including Uganda. Tolerance to artemisinins has already been
reported in South East Asia [35], and limiting the emergence and
spread of artemisinin resistance is of utmost importance [36].
Using a non-ACT regimen, such as AQ+SP, may be preferable for
IPT, allowing ACT regimens to be reserved for treatment of
symptomatic malaria. We found that AQ+SP was more efficacious
than expected given the poor performance of SP, which is
consistent with the results of other studies evaluating AQ+SP for
treatment [37,38] and prevention [10,13]. Provision of AQ+SP for
IPT once a school term (three times in one year) to Kenyan
schoolchildren reduced the rates of anemia by half and improved
children’s ability to concentrate in class [13]. Although use of
AQ+SP is likely to be increasingly limited by resistance [39], it
might be an option in areas where resistance to both drugs is
relatively low, particularly in West Africa, where AQ+SP remains
highly effective [10,40].
Safety and tolerability of regimens to be used in IPT programs
is a key issue, as they will be administered to asymptomatic
children. Serious toxicity has been associated with SP and AQ,
including severe cutaneous reactions with SP, and neutropenia
and hepatotoxicity with AQ, mainly with long-term chemopro-
phylaxis [41–43]. However, both drugs appear to be safer when
used in short-term treatment regimens [44,45]. In our study, no
serious adverse events occurred and all regimens appeared to be
safe. Children treated with AQ+SP were at increased risk of
early adverse events, particularly vomiting, suggesting that this
regimen was less well-tolerated. However, most children assigned
to AQ+SP reported willingness to take the medications,
suggesting that adverse events may not affect adherence to this
regimen. An association between AQ+SP and vomiting was also
observed in Senegal [12]. Notably, we did not find an association
between AQ+SP and risk of fatigue or weakness, which has
previously been reported in studies from Rwanda and Uganda
[46,47].
This trial had several important limitations. Firstly, we only
evaluated the effect of a single episode of treatment, limiting
inferences regarding the efficacy and safety of repeated doses.
Secondly, efficacy of the treatments was measured in terms of risk
of parasitemia, rather than incidence of clinical malaria, anemia,
or school performance, more typical endpoints for IPT studies.
Although we aim to inform IPT, this study is not a direct
assessment of IPT. Finally, our study was conducted in an area of
very high malaria transmission, and our results may not be
generalizable to regions with lower transmission intensity, and thus
lower antimalarial immunity.
In summary, DP and AQ+SP were both highly effective in
eliminating asymptomatic infections when administered as a single
dose to Ugandan schoolchildren, whereas SP alone was not
efficacious. DP was superior for preventing new infections. Our
results suggest that DP would be appropriate for use in IPT
programmes, but AQ+SP may be a suitable alternative in areas
where resistance to the individual drugs remains low. Future
research is needed to address additional operational questions
regarding IPT in schoolchildren, including optimal dosing
schedules in different settings, methods of delivery, and integration
of IPT with other existing school programs.
Supporting Information
Protocol S1 Study protocol.
Found at: doi:10.1371/journal.pone.0013438.s001 (0.86 MB
PDF)
Table 4. Risk of adverse events at 42 days in all participants by treatment group, and pairwise comparisons with placebo.
Placebo (N=196) SP (N=186) AQ+SP (N=200) DP (N=198)
% Risk (95% CI) % Risk (95% CI) p-value % Risk (95% CI) p-value % Risk (95% CI) p-value
Any adverse event 63.5 (56.6, 70.3) 61.2 (54.2, 68.4) 0.66 60.8 (54.1, 67.6) 0.59 59.1 (52.3, 66.0) 0.38
Fever/History of fever 7.9 (4.9, 12.8) 5.0 (2.7, 9.5) 0.26 3.5 (1.7, 7.2) 0.06 3.0 (1.4, 6.6) 0.03
Headache 24.3 (18.9, 31.0) 26.1 (20.4, 33.2) 0.68 25.5 (20.0, 32.1) 0.79 21.2 (16.2, 27.6) 0.47
Abdominal Pain 19.0 (14.2, 25.3) 16.9 (12.2, 23.2) 0.59 18.0 (13.3, 24.1) 0.80 17.7 (13.0, 23.8) 0.73
Nausea 7.2 (4.3, 11.9) 6.5 (3.8, 11.2) 0.80 12.5 (8.6, 17.9) 0.08 5.1 (2.8, 9.2) 0.37
Vomiting 4.7 (2.5, 8.8) 2.8 (1.2, 6.6) 0.34 13.0 (9.1, 18.5) 0.003 5.1 (2.8, 9.2) 0.87
Diarrhea 3.3 (1.5, 7.2) 3.3 (1.5, 7.2) 0.97 4.5 (2.4, 8.5) 0.53 5.1 (2.7, 9.2) 0.38
Cough 27.1 (21.3, 34.0) 17.2 (12.4, 23.5) 0.021 17.0 (12.5, 23.0) 0.017 17.2 (12.6, 23.2) 0.019
Coryza 13.3 (9.2, 19.0) 12.4 (8.3, 18.2) 0.80 9.0 (5.8, 13.9) 0.18 14.2 (10.0, 19.8) 0.80
Skin Rash/Pruritis 6.4 (3.7, 11.0) 8.2 (5.0, 13.2) 0.51 2.5 (1.1, 5.9) 0.06 5.6 (3.1, 9.8) 0.73
doi:10.1371/journal.pone.0013438.t004
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